At a glance
- Originator Asahi Kasei
- Developer Asahi Kasei; Nonindustrial source
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 15 Jan 2001 Asahi Chemical is now called Asahi Kasei
- 05 May 1997 Phase-II clinical trials for Rheumatoid arthritis in Japan (PO)